This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Advanced
User Guide

Save citation to file

Add to Collections

Name must be less than 100 characters
Unable to load your collection due to an error
Please try again

Add to My Bibliography

Unable to load your delegates due to an error
Please try again

Your saved search

Test search terms
Would you like email updates of new search results?
Saved Search Alert Radio Buttons
()

Create a file for external citation management software

Your RSS Feed

Review
. 2008 Jun;10(2):242-53.
doi: 10.1208/s12248-008-9028-5. Epub 2008 May 3.

Indolealkylamines: biotransformations and potential drug-drug interactions

Ai-Ming Yu  1
Affiliations

Affiliation

  • 1 Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, 541 Cooke Hall, Buffalo, New York, 14260-1200, USA. aimingyu@buffalo.edu
Review

Indolealkylamines: biotransformations and potential drug-drug interactions

Ai-Ming Yu. AAPS J. 2008 Jun.
. 2008 Jun;10(2):242-53.
doi: 10.1208/s12248-008-9028-5. Epub 2008 May 3.

Author

Ai-Ming Yu  1

Affiliation

  • 1 Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York, 541 Cooke Hall, Buffalo, New York, 14260-1200, USA. aimingyu@buffalo.edu

Abstract

Indolealkylamine (IAA) drugs are 5-hydroxytryptamine (5-HT or serotonin) analogs that mainly act on the serotonin system. Some IAAs are clinically utilized for antimigraine therapy, whereas other substances are notable as drugs of abuse. In the clinical evaluation of antimigraine triptan drugs, studies on their biotransformations and pharmacokinetics would facilitate the understanding and prevention of unwanted drug-drug interactions (DDIs). A stable, principal metabolite of an IAA drug of abuse could serve as a useful biomarker in assessing intoxication of the IAA substance. Studies on the metabolism of IAA drugs of abuse including lysergic acid amides, tryptamine derivatives and beta-carbolines are therefore emerging. An important role for polymorphic cytochrome P450 2D6 (CYP2D6) in the metabolism of IAA drugs of abuse has been revealed by recent studies, suggesting that variations in IAA metabolism, pharmaco- or toxicokinetics and dynamics can arise from distinct CYP2D6 status, and CYP2D6 polymorphism may represent an additional risk factor in the use of these IAA drugs. Furthermore, DDIs with IAA agents could occur additively at the pharmaco/toxicokinetic and dynamic levels, leading to severe or even fatal serotonin toxicity. In this review, the metabolism and potential DDIs of these therapeutic and abused IAA drugs are described.

PubMed Disclaimer

Figures

Fig. 1

Fig. 1

Chemical structures of the 5-HT…

Fig. 1

Chemical structures of the 5-HT neurotransmitter and some antimigraine triptan drugs

Fig. 1
Chemical structures of the 5-HT neurotransmitter and some antimigraine triptan drugs
Fig. 2

Fig. 2

Chemical structures of some indolealkylamine…

Fig. 2

Chemical structures of some indolealkylamine drugs of abuse that consist of d -lysergic…

Fig. 2
Chemical structures of some indolealkylamine drugs of abuse that consist of d-lysergic acid amides (e.g. LSD and LSA), tryptamine derivatives (e.g. psilocybin, DMT, bufotenine, 5-MeO-DMT and 5-MeO-DIPT), β-carbolines (e.g. harman, harmaline and harmine) and ibogaine
Fig. 3

Fig. 3

Biotransformation of an antimigraine triptan…

Fig. 3

Biotransformation of an antimigraine triptan drug, zolmitriptan. CYP1A2, cytochrome P450 1A2; MAO-A, monoamine…

Fig. 3
Biotransformation of an antimigraine triptan drug, zolmitriptan. CYP1A2, cytochrome P450 1A2; MAO-A, monoamine oxidase A; ALDH, aldehyde dehydrogenase
Fig. 4

Fig. 4

Metabolism of LSD. Note that…

Fig. 4

Metabolism of LSD. Note that the 2-oxo-3-hydroxy-LSD ( 2-oxo-3-HO-LSD ) has been shown…

Fig. 4
Metabolism of LSD. Note that the 2-oxo-3-hydroxy-LSD (2-oxo-3-HO-LSD) has been shown as a principal metabolite in the LSD-positive human urine samples
Fig. 5

Fig. 5

Deamination of bufotenine and 5-MeO-DMT…

Fig. 5

Deamination of bufotenine and 5-MeO-DMT produces corresponding indole acetic acid derivatives. 5-MeO-DMT can…

Fig. 5
Deamination of bufotenine and 5-MeO-DMT produces corresponding indole acetic acid derivatives. 5-MeO-DMT can be biotransformed to bufotenine through O-demethylation catalyzed primarily by CYP2D6, whereas bufotenine may be methylated to form 5-MeO-DMT
Fig. 6

Fig. 6

Metabolism of 5-MeO-DIPT. The O-demethylation…

Fig. 6

Metabolism of 5-MeO-DIPT. The O-demethylation is primarily mediated by CYP2D6 and N-deisopropylation is…

Fig. 6
Metabolism of 5-MeO-DIPT. The O-demethylation is primarily mediated by CYP2D6 and N-deisopropylation is catalyzed by CYP1A2, 2C8, 2C9, 2C19 and 3A4
Fig. 7

Fig. 7

Biotransformations of psilocybin and psilocin.…

Fig. 7

Biotransformations of psilocybin and psilocin. Psilocybin is dephosphorylated to produce psilocin that undergoes…

Fig. 7
Biotransformations of psilocybin and psilocin. Psilocybin is dephosphorylated to produce psilocin that undergoes deamination and glucuronidation
Fig. 8

Fig. 8

Metabolism of harmine. One major…

Fig. 8

Metabolism of harmine. One major pathway is O-demethylation mediated by CYP2D6, 1A and…

Fig. 8
Metabolism of harmine. One major pathway is O-demethylation mediated by CYP2D6, 1A and 2C enzymes, and the metabolite harmol is subject to glucuronidation and sulfation. Hydroxylated harmine metabolites have also been identified, which occur at the 6- and 3- or 4-positions of harmine
Fig. 9

Fig. 9

Serotonergic neurotransmission. Hyperserotonergic effects may…

Fig. 9

Serotonergic neurotransmission. Hyperserotonergic effects may be induced when a tryptamine derivative (5-HT receptor…

Fig. 9
Serotonergic neurotransmission. Hyperserotonergic effects may be induced when a tryptamine derivative (5-HT receptor agonist) and a β-carboline (monoamine oxidase inhibitor) are used concurrently. In particular, the β-carboline can reduce the degradation of 5-HT neurotransmitter and inhibit the metabolism of tryptamine derivative
See this image and copyright information in PMC

References

    1. Silberstein S. D., McCrory D. C. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003;43(2):144–166. doi: 10.1046/j.1526-4610.2003.03034.x. - DOI - PubMed
    1. Jhee S. S., Shiovitz T., Crawford A. W., Cutler N. R. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin. Pharmacokinet. 2001;40(3):189–205. doi: 10.2165/00003088-200140030-00004. - DOI - PubMed
    1. Dahlof C. Integrating the triptans into clinical practice. Curr. Opin. Neurol. 2002;15(3):317–322. doi: 10.1097/00019052-200206000-00015. - DOI - PubMed
    1. Shulgin A. T., Shulgin A. TIKAL The Continuation. Berkeley, CA: Transform; 1997.
    1. Aghajanian G. K., Marek G. J. Serotonin and hallucinogens. Neuropsychopharmacology. 1999;21(2 Suppl):16S–23S. - PubMed

Publication types

MeSH terms

LinkOut - more resources

Full text links
Springer full text link Springer Free PMC article
Cite
Morty Proxy This is a proxified and sanitized view of the page, visit original site.